Disease Overview：Arrhythmogenic Right Ventricular Cardiomyopathy（ARVC）
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a rare, inherited cardiomyopathy characterized by progressive fibrofatty replacement of the right ventricular myocardium, leading to ventricular arrhythmias, right ventricular dysfunction, and an increased risk of sudden cardiac death—particularly in young adults and athletes. Diagnosis relies on a combination of electrocardiographic abnormalities (e.g., epsilon waves, prolonged QRS duration), imaging findings (right ventricular dilation/dysfunction on cardiac MRI or echocardiography), signal-averaged ECG, and genetic testing for pathogenic variants in desmosomal genes (e.g., PKP2, DSP, DSG2). Management is multidisciplinary and includes antiarrhythmic therapy, implantable cardioverter-defibrillator (ICD) placement for secondary prevention or high-risk primary prevention, catheter ablation for recurrent ventricular tachycardia, and, in advanced cases, heart transplantation. Long-term surveillance and family screening are essential components of care.
China offers distinct advantages for ARVC management: its top-tier cardiovascular centers—such as Fuwai Hospital (National Center for Cardiovascular Diseases) and Shanghai Ruijin Hospital—boast internationally trained electrophysiologists with extensive experience in complex substrate-based VT ablation and ICD optimization. Advanced 3D electroanatomic mapping systems (e.g., CARTO, EnSite Precision), high-resolution cardiac MRI protocols, and next-generation genetic sequencing are routinely deployed. Clinical outcomes align with global benchmarks: multi-center studies report >85% freedom from recurrent VT at 2-year follow-up post-ablation in carefully selected ARVC patients. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based standards. As a dedicated medical tourism agency, we facilitate seamless access for international patients—handling hospital referrals, coordinating pre-arrival diagnostics, ensuring transparent all-inclusive pricing, arranging visa support, and providing bilingual clinical coordination and post-discharge follow-up.
Arrhythmogenic Right Ventricular Cardiomyopathy: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Non-Surgical / Conservative Management
*Target Criteria:* Asymptomatic carriers, mild ventricular ectopy, preserved RV function (RVEF >45%), no syncope or sustained VT.
- •Beta-blockers (e.g., metoprolol): ¥120–¥360/month ($17–$52)
- •Antiarrhythmics (sotalol, amiodarone): ¥280–¥950/month ($40–$136)
- •Annual monitoring package: ECG + Holter + echocardiogram + cardiac MRI (1.5T) + NT-proBNP + troponin I: ¥4,200–¥6,800 ($600–$970)
- •Genetic counseling & cascade testing (first-degree relatives): ¥1,800–¥3,200 per person ($257–$457)
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Documented sustained VT/VF, recurrent ICD shocks (>2/year), drug-refractory arrhythmia, RVEF <40%, or progressive RV dilation/dysfunction.
- •Implantable Cardioverter-Defibrillator (ICD):
- Device implantation (single-chamber transvenous): ¥82,000–¥125,000 ($11,700–$17,800) - Dual-chamber/ICD with CRT capability: ¥138,000–¥172,000 ($19,700–$24,500)
- •Catheter Ablation (Substrate-based VT ablation):
- Ablation procedure (RF/cryo, ≥2 lesions): ¥48,000–¥76,000 ($6,850–$10,850) - Post-procedure 72-hr telemetry & biomarker monitoring: ¥1,600 ($230)
Special / Complex Condition Options
- •Advanced heart failure (RVEF <25%, NYHA III–IV):
- Evaluation for heart transplantation: ¥12,500–¥18,000 ($1,780–$2,570) — includes right heart catheterization, donor matching, and immunologic profiling.
- •Biventricular involvement or left-dominant ARVC:
Quick Selection Guide
- •<35 years, asymptomatic, genotype-positive: Start with beta-blocker + annual MRI monitoring ($600–$970/year); avoid ICD unless inducible VT on EP study.
- •45–65 years, recurrent VT, ICD-dependent: Prioritize substrate ablation ($6,850–$10,850) to reduce shocks—cost-effective vs. lifelong device replacements.
- •>70 years or severe comorbidities (COPD, CKD stage 4): Conservative rhythm control + palliative ICD programming (no shock therapy); total annual cost ≈ $1,200–$2,100.
- •Budget-constrained (<$5,000 USD/year): Beta-blocker + Holter + echo (no MRI); defer ICD unless syncope or VF arrest—monitor closely for RV functional decline.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Arrhythmogenic Right Ventricular Cardiomyopathy Medical Vacation Packages
Curated transparent all-inclusive packages combining Arrhythmogenic Right Ventricular Cardiomyopathy treatment with China top medical destinations:
